Capricor Therapeutics Inc (CAPR)

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing cell- and exosome-based therapies for duchenne muscular dystrophy (DMD) and other diseases with significant unmet medical need in the United States. Its lead candidate, Deramiocel, is an allogeneic cardiosphere-derived cell therapy being evaluated in a phase 3 clinical trial for DMD. The company is also advancing exosome-based programs, including an exosome protein vaccine candidate under preclinical study for SARS-CoV-2, the StealthX Exosome Platform, and StealthX, an engineered exosome-based vaccine candidate in phase 1 clinical development for potential use in targeted RNA, protein, and small molecule therapeutics. Capricor has licensing arrangements with Johns Hopkins University, the University of Rome, and Cedars-Sinai Medical Center, along with a Cell Line License Agreement with Life Technologies. Founded in 2005, the company is headquartered in San Diego, California.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.